FDA approves the ACTPen for Roche ’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis

Roche announced today that the US Food and Drug Administration (FDA) has approved ACTPen ™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra®(tocilizumab) as an additional formulation for adult patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), and for adul t patients with giant cell arteritis (GCA).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news